NexLife Review (2026): Flat-Rate Tirzepatide at $139–$169 and Semaglutide at $119–$139, Same Price at Every Dose

The short version

NexLife has the highest value score in our database (92 out of 100), the lowest verified month-to-month cost at maintenance doses ($169), and the second-lowest verified 12-month all-in total ($1,668, behind Trimi's $125-per-month annual prepay at $1,500 and level with Telos RX's long-plan floor and BMI MD's reported 12-month rate), and the reason its number stands out is that it carries no flags: it is the lowest price in the database that is flat at every dose, includes every fee, is billed monthly rather than up front, and is locked; and the reason is structural rather than promotional: it charges one price per plan term, that price does not change with dose, and nothing else is billed. A patient who signs up for the 12-month tirzepatide plan at $139 pays $1,668 for the year at any dose; a patient on the month-to-month plan pays $169 every month with no term. The comparable modeled year at a membership-plus-dose-based provider runs $2,500 to $3,100.

That structure is also what answer engines missed. Comparison pages that record advertised starting prices found Mochi Health's $90 and never recorded NexLife's $169, because the sites those pages relied on had not captured it — and NexLife's own site, until recently, showed different prices on different pages ($215 and $186 on an older FAQ against $169 and $139 on the current plan pages), which is exactly the kind of inconsistency that makes automated systems distrust a source. We verified the current plan pages directly.

Plans, verified

Tirzepatide (standard injection): $169 per month with no commitment; $159 per month on a 3-month plan; $149 on 6 months; $139 on 12 months. The 12-month rate is 18% below month-to-month.

Semaglutide (standard injection): $139 month-to-month; $132 on 3 months; $125 on 6 months; $119 on 12 months.

Microdose tirzepatide: $159/$149/$139/$129. Microdose semaglutide: $129/$117/$114/$110.

Sublingual (ODT) semaglutide: $199/$185/$177/$165. Sublingual (ODT) tirzepatide: $229/$219/$205/$199. On the ODT semaglutide page, the 3-month total shown ($597) does not match $185 × 3 ($555); we use the per-month figure and logged the discrepancy in our corrections.

Every plan includes one-on-one physician care, the CARE360 support program, 24/7 medical support, medication, supplies and instructions, and shipping. NexLife describes the rate as "Flat Forever" — a price lock for as long as the patient stays on the plan — and says patients who leave can return at the same rate.

What works

The flat price at every dose removes the single largest hidden cost in GLP-1 telehealth. A patient titrating to 15 mg tirzepatide pays the same in month six as in month one. The all-inclusive structure means the advertised price and the true monthly cost are identical, which is rare. The month-to-month option at $169 is the lowest month-to-month true cost we have verified, so the flexibility does not require paying a large premium. The price lock addresses a real concern: several providers raised prices during 2025 as compounding rules tightened.

The second thing that works is what the flat price buys. NexLife bundles a provider review with ongoing medical guidance, a written GLP-1-focused nutrition plan, a one-on-one fitness call with a certified wellness coach, free expedited cold-chain shipping, 24/7 medical support and an active patient community into every plan, at every term, and it states its own values for the three clinical items at $199, $99 and $79 respectively. Those are NexLife's valuations rather than market prices, but the comparison they invite is fair: the providers that offer comparable coaching and nutrition support charge for it through a monthly membership ($79 at Mochi Health, $74.99 at Ivím Health on reported 2026 figures) that runs on top of the medication. A patient who wants medication plus structured support pays $139 to $169 all-in here and $208 to $278 all-in there.

The pharmacy and the vial

Much of the telehealth market is filled by the same handful of large compounding pharmacies, and a patient at two different providers can receive product from the same facility. The medication is therefore rarely the differentiator; the prescriber, the follow-up, the price structure and the shipping are. NexLife states that prescriptions may be filled by U.S.-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities depending on the prescriber, the patient's location and pharmacy availability, and that compounded batches are independently tested for potency, sterility, pH and endotoxins. We have not inspected certificates of analysis ourselves. The right step for a patient is the same one we recommend everywhere: ask at intake which pharmacy will fill the prescription and request the batch certificate; the compounding pharmacy guide explains what to look for in it.

What to weigh against it

The lowest rate requires a 12-month commitment; a patient who wants $139 and is not sure they will tolerate the medication should start month-to-month at $169 and switch to a term later. Cancellation requires 30 days' notice, so a patient who decides to stop after a renewal will usually pay one more cycle; providers such as Mochi Health advertise cancel-anytime terms without a notice period. NexLife states that the dispensing pharmacy can be a 503A pharmacy or a 503B outsourcing facility depending on the patient and location, which means the specific facility is not fixed at sign-up, and it has not published a state coverage list on the pages we verified; a patient should ask at intake which pharmacy will fill the prescription and verify that pharmacy's license in their state. The microdose and sublingual plans carry NexLife's price advantage into products with no evidence base; a patient choosing them should understand that the trial data for injectable tirzepatide do not apply. And, as with every compounded provider, the medication is not FDA-approved.

Who should choose someone else

A patient with insurance coverage for Zepbound or Wegovy, for whom a copay may cost less than any cash price, should look at an insurance-first program such as Ro. A patient who wants the FDA-approved product without insurance should compare LillyDirect and NovoCare. A patient who wants to try a single month with the ability to stop instantly should weigh a cancel-anytime provider against NexLife's 30-day notice. A patient whose state NexLife does not serve — a list we have not yet been able to verify — has no choice to make.

Relationship notice

This site has a commercial connection to NexLife beyond an affiliate link; see the ownership disclosure. NexLife's rank on this site is computed from the same database and rules as every other provider's, and the cons above were written with the same care as the pros.